Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,900 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $27.54 per share, for a total transaction of $79,866.00. Following the purchase, the chief executive officer directly owned 5,602,302 shares of the company’s stock, valued at approximately $154,287,397.08. This trade represents a 0.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Wednesday, December 31st, Snehal Patel purchased 4,300 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $21.36 per share, with a total value of $91,848.00.
• On Tuesday, December 30th, Snehal Patel purchased 2,900 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $21.73 per share, for a total transaction of $63,017.00.
• On Thursday, December 18th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $12.62 per share, for a total transaction of $51,742.00.
• On Tuesday, November 25th, Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.37 per share, with a total value of $38,502.00.
• On Friday, November 7th, Snehal Patel bought 10,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel purchased 2,300 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.26 per share, for a total transaction of $21,298.00.

Greenwich LifeSciences Trading Up 8.2%

NASDAQ:GLSI opened at $29.02 on Wednesday. The company has a 50-day moving average of $13.24 and a 200-day moving average of $11.71. The firm has a market cap of $401.93 million, a price-to-earnings ratio of -19.88 and a beta of 1.47. Greenwich LifeSciences, Inc. has a twelve month low of $7.78 and a twelve month high of $30.82.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.30). On average, research analysts forecast that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GLSI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, HC Wainwright lifted their target price on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Greenwich LifeSciences currently has a consensus rating of “Hold” and an average target price of $47.50.

Institutional Trading of Greenwich LifeSciences

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Greenwich LifeSciences by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares during the period. Geode Capital Management LLC grew its holdings in shares of Greenwich LifeSciences by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after acquiring an additional 1,972 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Greenwich LifeSciences in the second quarter worth $509,000. Citadel Advisors LLC increased its stake in shares of Greenwich LifeSciences by 52.1% in the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock worth $208,000 after acquiring an additional 7,174 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Greenwich LifeSciences during the first quarter worth $177,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.